Minimally Invasive Techniques for the Treatment of Patients with Structural Heart Disease

Author(s): David Begley

DOI: 10.2174/978160805119911101010107

The Use of Left Atrial Appendage Occlusion Devices

Pp: 107-112 (6)

Buy Chapters

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

Atrial fibrillation is the commonest sustained arrhythmia and is the commonest cause of stroke due to embolization of thrombi from the left atrium. Risk of stroke increases with age and other co-morbidities and can be reduced by oral anticoagulation with warfarin. However warfarin has a narrow therapeutic window and can be affected by drugs and some foods, resulting in many patients being inadequately anti-coagulated. In addition other patients may have contra-indications to its use. Surgical and echocardiographic studies have demonstrated the source of thrombi to be the left atrial appendage in over 90% of cases. Therefore excluding the left atrial appendage from the systemic circulation may be a viable alternative to anti-coagulation in reducing the risk of stroke.

Three devices have been developed for percutaneous deployment to exclude the left atrial appendage. The Percutaneous Left Atrial Appendage Transcatheter Occlusion System - PLAATO (ev3), Watchman (Aritech) and Amplatzer Cardiac Plug (AGA Medical) are all delivered via the femoral vein with transpetal access to the left atrium. Each consists of a self-expanding nitinol mesh which is lodged in the left atrial appendage occluding the appendage and allowing endothelialisation of the atrial facing surface.

Early non-randomized studies demonstrated the technique to be simple and feasible with acceptable risks associated with implantation. A recent randomized controlled trial comparing device occlusion of the appendage to warfarin demonstrated that the device was at least non-inferior to warfarin in preventing stroke in non-valvular atrial fibrillation.

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books